CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 28 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $72,000 | -17.2% | 90,300 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $87,000 | -46.3% | 90,300 | -10.9% | 0.00% | -50.0% |
| Q1 2017 | $162,000 | -55.7% | 101,347 | 0.0% | 0.00% | -60.0% |
| Q4 2016 | $366,000 | +15.8% | 101,347 | +97.4% | 0.01% | 0.0% |
| Q3 2016 | $316,000 | +209.8% | 51,347 | +85.4% | 0.01% | +150.0% |
| Q2 2016 | $102,000 | – | 27,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $4,572,000 | 5.05% |
| Clarus Ventures, LLC | 2,752,488 | $4,404,000 | 3.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 388,030 | $621,000 | 0.12% |
| Rhenman & Partners Asset Management AB | 310,756 | $497,000 | 0.08% |
| BOSTON FAMILY OFFICE LLC | 24,467 | $39,000 | 0.01% |
| OPPENHEIMER & CO INC | 90,000 | $144,000 | 0.00% |
| Alyeska Investment Group, L.P. | 221,281 | $354,000 | 0.00% |
| A.R.T. Advisors, LLC | 46,747 | $74,000 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 101,347 | $162,000 | 0.00% |
| Acrospire Investment Management LLC | 680 | $1,000 | 0.00% |